I 
116TH CONGRESS 
2D SESSION 
H. R. 6383 
To provide for research and education with respect to uterine fibroids, and 
for other purposes. 
IN THE HOUSE OF REPRESENTATIVES 
MARCH 24, 2020 
Ms. CLARKE of New York (for herself, Ms. KELLY of Illinois, Mrs. WATSON 
COLEMAN, Mr. DAVID SCOTT of Georgia, Ms. LEE of California, Ms. 
PLASKETT, Ms. FUDGE, Ms. JOHNSON of Texas, Mr. RUSH, Mr. BROWN 
of Maryland, Ms. PRESSLEY, Mr. DANNY K. DAVIS of Illinois, Mr. 
THOMPSON
of Mississippi, Mr. CLYBURN, Mr. RICHMOND, Mr. 
BUTTERFIELD, Mr. BISHOP of Georgia, Mr. CLEAVER, Mr. HASTINGS, 
Mr. JEFFRIES, Mr. MEEKS, Mr. CARSON of Indiana, Ms. JACKSON LEE, 
Mr. JOHNSON of Georgia, Mrs. LAWRENCE, Ms. BASS, and Ms. NORTON) 
introduced the following bill; which was referred to the Committee on En-
ergy and Commerce 
A BILL 
To provide for research and education with respect to uterine 
fibroids, and for other purposes. 
Be it enacted by the Senate and House of Representa-
tives of the United States of America in Congress assembled, 
SECTION 1. SHORT TITLE. 
This Act may be cited as the ‘‘Uterine Fibroid Re-
search and Education Act of 2020’’. 
VerDate Sep 11 2014 
18:26 Apr 09, 2020
Jkt 099200
PO 00000
Frm 00001
Fmt 6652
Sfmt 6201
E:\BILLS\H6383.IH
H6383
pamtmann on DSKBC07HB2PROD with BILLS
SEC. 2. FINDINGS. 
Congress finds as follows: 
(1) It is estimated that between 20 and 30 per-
cent of women of reproductive age have clinically 
recognized uterine fibroids, and screening studies in-
dicate the prevalence of uterine fibroids in women 
may be much higher. 
(2) In the United States, an estimated 
26,000,000 women between the ages of 15 and 50 
have uterine fibroids. Uterine fibroids may cause sig-
nificant morbidity through their presence in the 
uterus and pelvic cavity, causing significant pelvic 
pain, iron-deficiency anemia, miscarriages, infer-
tility, and heavy bleeding—one of the most common 
and bothersome symptoms. 
(3) The pain, discomfort, stress, and other 
physical and emotional symptoms of living with 
fibroids may significantly interfere with a woman’s 
quality of life, compromising her ability to function 
normally or work or care for her family, and may 
lead to more severe health and wellness issues. 
(4) The development of uterine fibroids is a 
common and significant health problem, affecting 
women, primarily of reproductive age, across all 
ages, racial backgrounds, and socioeconomic levels. 
VerDate Sep 11 2014 
18:26 Apr 09, 2020
Jkt 099200
PO 00000
Frm 00002
Fmt 6652
Sfmt 6201
E:\BILLS\H6383.IH
H6383
pamtmann on DSKBC07HB2PROD with BILLS
(5) Most women will experience uterine fibroids 
by the age of 50, yet few data exist describing the 
overall patient experience with fibroids. Women with 
fibroids or symptoms suggestive of fibroids experi-
ence significant distress that reduces quality of life 
and many women are likely undiagnosed, under-
scoring the need for improved awareness and edu-
cation. 
(6) Minority women are more likely to develop 
uterine fibroids. It is estimated that more than 80 
percent of African-American women and about 70 
percent of Caucasian women develop fibroids by the 
time they reach menopause. African-American 
women have also been shown to have more severe 
symptoms and develop early-onset uterine fibroids 
that develop into larger tumors. 
(7) The exact number of affected women is un-
known, because only 1 out of 4 women who have a 
uterine fibroid tumor exhibit symptoms severe 
enough to require treatment. 
(8) Current research and available data do not 
provide adequate information on the rates of preva-
lence and incidence of fibroids in Asian, Hispanic, 
and African-American minority women. There is no 
quantitative data available in regard to the costs as-
VerDate Sep 11 2014 
18:26 Apr 09, 2020
Jkt 099200
PO 00000
Frm 00003
Fmt 6652
Sfmt 6201
E:\BILLS\H6383.IH
H6383
pamtmann on DSKBC07HB2PROD with BILLS